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2 Division of HIV and Other Retroviruses, Robert Koch-Institute, Berlin, Germany, 3 Holy Family Virika Hospital,




Since 2012, WHO guidelines for the prevention of mother-to-child transmission (PMTCT) of
HIV-1 in resource-limited settings recommend the initiation of lifelong antiretroviral combina-
tion therapy (cART) for all pregnant HIV-1 positive women independent of CD4 count and
WHO clinical stage (Option B+). However, long-term outcomes regarding development of
drug resistance are lacking until now. Therefore, we analysed the emergence of drug resis-
tance mutations (DRMs) in women initiating Option B+ in Fort Portal, Uganda, at 12 and 18
months postpartum (ppm).
Methods and findings
124 HIV-1 positive pregnant women were enrolled within antenatal care services in Fort Por-
tal, Uganda. Blood samples were collected at the first visit prior starting Option B+ and post-
partum at week six, month six, 12 and 18. Viral load was determined by real-time RT-PCR.
An RT-PCR covering resistance associated positions in the protease and reverse transcrip-
tase HIV-1 genomic region was performed. PCR-positive samples at 12/18 ppm and respec-
tive baseline samples were analysed by next generation sequencing regarding HIV-1 drug
resistant variants including low-frequency variants. Furthermore, vertical transmission of
HIV-1 was analysed. 49/124 (39.5%) women were included into the DRM analysis. Viro-
logical failure, defined as >1000 copies HIV-1 RNA/ml, was observed in three and seven
women at 12 and 18 ppm, respectively. Sequences were obtained for three and six of these.
In total, DRMs were detected in 3/49 (6.1%) women. Two women displayed dual-class resis-
tance against all recommended first-line regimen drugs. Of 49 mother-infant-pairs no infant
was HIV-1 positive at 12 or 18 ppm.
Conclusion
Our findings suggest that the WHO-recommended Option B+ for PMTCT is effective in a
cohort of Ugandan HIV-1 positive pregnant women with regard to the low selection rate of
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DRMs and vertical transmission. Therefore, these results are encouraging for other coun-
tries considering the implementation of lifelong cART for all pregnant HIV-1 positive women.
Introduction
Mother-to-child transmission (MTCT) is the most common way of HIV-1 infection among chil-
dren under the age of 15[1, 2]. Vertical transmission of the virus can occur during pregnancy,
labour and delivery or through breastfeeding. Without any intervention, the risk of transmission
ranges between 15% and 45%. Since the end of the last century, the use of antiretroviral (ARV)
drugs for the prevention of mother-to-child transmission (PMTCT) has unfolded a potential to
reduce the rate of MTCT to<5% [1, 3–5]. However, the frequent emergence of drug resistance
mutations (DRMs) linked with temporary single- or combination- ARV regimens has to be
viewed as a major threat for future treatment success in mothers and their children by reducing
the susceptibility to ARV drugs[6–11]. Even in complex PMTCT regimens with longer intake
duration, the level of acquired DRMs remains high as long as they are applied only temporarily,
as discontinuing ARV intake after delivery and possible restart during subsequent pregnancies
or for later antiretroviral therapy (ART) promotes the emergence of DRMs[12, 13].
Since 2012, the WHO PMTCT guidelines recommend “Option B+”, which stands for the
initiation of lifelong combination ART (cART) for all pregnant and breastfeeding women liv-
ing with HIV-1 regardless of CD4 count or WHO clinical stage[14]. The recommended regi-
men consists of two nucleoside reverse transcriptase inhibitors (NRTIs) combined with a non-
nucleoside reverse transcriptase inhibitor (NNRTI) (first-line regimen), or a protease inhibitor
(PI) (second-line regimen). Infants born to HIV-1-infected mothers also receive nevirapine
(NVP, an NNRTI) or zidovudine from birth until six weeks of age. While the early start and
lifelong intake of cART increases the effectiveness regarding PMTCT by lastingly suppressing
viral loads[15], the approach also focuses on improving maternal health and reducing mortal-
ity and morbidity of HIV-1 positive women. The continuous intake of cART is reported to
decrease or avoid resistance development[16], but suboptimal adherence and loss to follow-up
due to individual, structural or community factors still pose a risk for the selection of drug
resistance even under Option B+[17, 18]. Besides the need to overcome this huge barrier, sur-
veillance of DRMs is a key factor to optimize treatment outcomes and support national,
regional and global decision-making regarding the choice of first-line regimens[6].
Until now, population-based Sanger sequencing has been the gold standard for the screen-
ing of HIV-1 genotypic resistance. However, population-based sequencing is not able to detect
low-frequency HIV-1 drug resistant variants at levels below 20%[12]. Nevertheless, studies
show that also low-frequency HIV-1 drug resistant variants can have an influence on the suc-
cess of cART[8, 19]. With its high analytical sensitivity, next generation sequencing (NGS) has
overcome the limitations of traditional Sanger sequencing and therefore gained increasing
importance in the last years[20–22].
Uganda is classified as a HIV-1 high burden country with a prevalence around 7.4% in the
general population in 2013[23]. In 2012 Uganda started implementing Option B+ which was
scaled-up countrywide since then, increasing the percentage of pregnant women under ART
from 86% in 2011 to 94% in 2014[23]. Until now, long-term data on resistance development
during intake of Option B+ in a real-life scenario are scarce. In fact, there is only one study
from Malawi, reporting DRMs in 8.5% of women at 12 months postpartum (ppm)[24].
The aim of this study was to assess the emergence of HIV-1 DRMs against three major drug
classes, NRTIs, NNRTIs and PIs, leading to resistance against the recommended first- and sec-
ond-line drugs for PMTCT in Fort Portal, Uganda. Using a combination of conventional and
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real-time RT-PCR assays as well as the NGS platform MiSeq (Illumina) the development and
variation in time of DRMs could be assessed.
Materials and methods
Ethic statement
Ethical approval was obtained from the Committee of Higher Degrees, Research and Ethics,
College of Health Sciences, Makerere University Kampala, by the Ugandan National Council
for Science and Technology and by the Ethical Committee of Charité - Universitätsmedizin
Berlin. We obtained informed written consent from all participants involved in the study and
treated data strictly confidential. Participants could withdraw their study participation at all
times without any negative consequences for their treatment in hospital.
Clinical samples and study design
Between January 2013 and December 2013, women attending antenatal care (ANC) at Virika
Hospital and the Regional Referral Hospital in Fort Portal, Uganda, were recruited for a longitu-
dinal prospective cohort study as a part of a larger study on Option B+ outcomes. According to
the WHO and Ugandan PMTCT guidelines from 2012, HIV-1 positive pregnant women were
enrolled on Option B+, composed of a single-pill based on a NRTI/NNRTI, fixed-dose combina-
tion of efavirenz/lamivudine/tenofovir (EFV/3TC/TDF) as first-line regimen; newborns received
NVP from birth up to six weeks of life, regardless of infant feeding method[14]. Women were
included in the study due to following eligibility criteria: Informed written consent, age18
years, confirmed pregnancy and positive HIV-1 status without prior ART enrolment.
Women were followed-up at subsequent ANC and postpartal care visits until 18 ppm.
Plasma samples from women were collected at the first ANC visit before initiating Option
B+ (baseline sample), at subsequent ANC visits, at six weeks postpartum (ppw) as well as six,
12 and 18 ppm. From infants, plasma samples were obtained or blood from heel pricks was
spotted onto filter papers (Dried Blood Spots, DBS) at the same time intervals. In the present
study, which aims to analyse the emergence of DRMs at least 1 year after initiation of Option B
+ in ANC only women with a sample at 12 and/or 18 ppm and a respective baseline sample
available were included.
Extraction of viral nucleic acids
Nucleic acids were extracted using the NucliSens easyMAG system (Biomerieux) according to
the manufacturer‘s instructions. Briefly, plasma samples were centrifuged for 10 min at 4˚C
with 3000 g to remove cryoprecipitate. Subsequently, 500μl of plasma were transferred into 2
ml of lysis buffer, mixed and incubated at room temperature for 10 min. After adding 100 μl of
magnetic silica solution, total nucleic acids were extracted by automated magnetic separation
(Generic 2.0.1) and finally eluted in 60 μl of elution buffer. Extracted nucleic acids were ali-
quoted in portions of 10 μl and immediately stored at -80˚C until further use.
For the extraction of total nucleic acids from DBS, 2 blood spots (50 μl blood each) were cut
out from the filter paper and transferred to 2 ml of lysis buffer. After shaking for one hour at
room temperature with 300 rpm, 1.8 ml of lysated eluate was used for automated nucleic acid
extraction performed as described above.
Amplification of nucleic acids
For amplification of viral RNA three different PCRs were performed; two conventional
RT-PCR assays to identify DMRs in the protease (PR) and reverse transcriptase (RT) genomic
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region of the HIV-1 polymerase (pol)-region and a real-time TaqMan RT-PCR to determine
the HIV-1 viral load. With the priority of obtaining as many sequences as possible for DRM
analysis and due to the limited material available, first conventional RT-PCR assays were per-
formed, followed by HIV-1 viral load measurement.
For conventional RT-PCR two overlapping fragments of 576 bp length (fragment 1) con-
taining the codons 1 to 99 of the PR and codons 1 to 93 of the RT and of 718 bp length (frag-
ment 2) containing the codons 22 to 260 of the RT [25] were amplified using the Qiagen One
Step RT PCR kit and an Eppendorf Mastercycler pro. The resulting PR-RT sequence (fragment
1+2, position 2277–3302 on HXB2 genome, Acc. No. K03455.1) covers all resistance-associ-
ated mutations of PR and RT. In the following text viral sequences named “PR”, “RT” and
“PR-RT” refer to the corresponding PCR-product of “fragment 1, 2 or 1+2”.
Conventional RT-PCR assays were performed on all maternal 12 and 18 ppm samples as
well as respective baseline samples. Additional samples from earlier time points (6 ppw or
6 ppm) were subjected to the PCRs if maternal HIV-1 sequences displayed DRMs. Samples
resulting in RT-PCR fragments were applied to NGS. Infant 12/18 ppm samples were analysed
by conventional RT-PCR. In case of a positive result infants were considered to be HIV-1
infected.
The HIV-1 viral load was determined using a quantitative real-time TaqMan RT-PCR
(MX3005P qPCR system from Agilent) with primers located in the long terminal repeat (LTR)
of the HIV-1 genome. Primers and probe for the amplification of a 118 base pair (bp) fragment
were used as described by Cleland et al., 2001[26]. An external standard curve generated from
known concentrations of the laboratory strain HTLVIIIB (Acc. No. K03455.1) was carried out
on each plate to enable absolute quantification of HIV-1 genome equivalents in every sample.
Viral load was determined for all maternal baseline samples and post partum samples resulting
in RT-PCR fragments. In this study, samples with HIV-1 viral loads >1000 copies/ml were
defined being a result of “virological failure” (VF).
Next generation sequencing (NGS)
Amplicons were purified using Agencourt AMPure1 XP Beads (Beckman Coulter) and quan-
tified using Quant-iT™ PicoGreen1 dsDNA Reagent (Invitrogen). The Nextera XT1 kit (Illu-
mina) was used to prepare the NGS libraries. Sequencing was performed on the Illumina
MiSeq1 employing the 2 x 200 or 2 x 300 bp paired end modus. The NGS data were processed
through an in-house bioinformatics pipeline making use of the tools Trimmomatic (version
0.33)[27], FLASH (version 1.2.11)[28], and BWA (version 0.7.10)[29], all wrapped in a Python
script. After adapter-clipping, trimming and merging, five iterations of mapping against a ref-
erence sequence (HXB2, Acc. No. K03455.1) were performed. Potential insertions and dele-
tions were considered during the mapping cycles. The final output was subject to further
Python scripts, which enabled codon-based variant detection and generation of a consensus
sequence containing ambiguities according to an adjustable threshold. A Sanger-like threshold
of 20% was applied in general. Moreover, the sensitivity and specificity for the detection of
low-frequency drug resistant variants was determined using mixtures of recombinant HIV-1
from the wild-type pNL4.3 clone (Acc. No. M19921) and a mutant pNL4.3 derived clone that
harbours twelve DRMs within pol. Cloning and generation of the recombinant virus has been
described previously[6, 30]. Twenty-eight mixtures ranging from 1% to 50% mutant in wild
type were prepared in viral loads ranging from 103 to 106 copies/ml. In mixtures with viral
loads <105 copies/ml, the sensitivity of detection varied and the noise was higher than in mix-
tures with viral loads105 copies/ml. Consequently, NGS thresholds for low-frequency vari-
ants of 3% and 10% for samples with low and high viral load, respectively, were determined.
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Detection of viral drug resistance mutations and determination of HIV-1
subtype
Only samples with successfully generated sequence were included in the final DRM-analysis.
DRMs were determined according to the Stanford University’s HIV-1 drug resistance data-
base[31] and by the International Antiviral Society USA (IAS-USA)[32].
The prevalence of pre-existing transmitted drug resistance mutations (TDRMs) in baseline
samples was assessed using the WHO surveillance drug resistance mutations list (SDRM)[33].
Therefore, resistance mutations in the PR and RT were considered.
In contrast, the prevalence of DRMs selected by the implemented NRTI/NNRTI regimen was
only analysed in the viral RT sequence of post partum samples, as no selection of DRMs in PR
was expected. Based on sequence availability, comparison of viral RT sequences from baseline
samples to respective sequences from follow-up (FUP) samples after delivery was performed to
identify emerging DRMs acquired during the PMTCT regimen. However, the extent of DRM-
selection in FUP samples without the respective baseline sequence could be assessed by monitor-
ing their proportion compared to the respective 6 ppw and 6 ppm samples. Drug resistant low-fre-
quency variants were defined as DRMs detected by NGS below the Sanger-like cut-off of 20%.
HIV-1 subtypes were determined on basis of the Sanger-like NGS sequences with an ambi-




124 women attending ANC between January and December 2013 were tested HIV-1 positive.
All women were drug naïve at enrolment and received the recommended first-line regimen
consisting of EFV/3TC/TDF. Socio-demographic and clinical baseline data, as well as informa-
tion on the antenatal adherence of the study group were published by Schnack et al., 2016[35].
Only 59/124 (47.6%) women completed the study-period at 18 or at least 12 ppm. However,
ten of them were excluded due to missing baseline samples. These 49 women finally consti-
tuted to the present study cohort for genotypic resistance testing (Fig 1). Both, the 12 and
18 ppm sample were available for 39 women, while either the 12 or 18 ppm sample was avail-
able for six and four women, respectively, resulting in overall 49 women with 45 samples from
12 ppm and 43 samples from 18 ppm. Baseline, 6 ppw and 6 ppm samples were available for
49/49, 43/49 and 44/49 women, respectively (6 ppw and 6 ppm not shown in Fig 1).
Analysing the last available sample of involved infants, in 43 infants at 18 ppm and six
infants at 12 ppm, no HIV-1 infection was detected.
Genotypic resistance testing and virological failure
Assessment of TDRMs was carried out for 35/49 RT-PCR positive baseline samples, resulting
in 27 PR-RT sequences, six PR sequences, and two RT sequences (Table 1).
Furthermore, PR-RT sequences could be obtained for 2/3 samples at 6 ppw, 3/3 samples at
6 ppm, 5/5 samples at 12 ppm and 5/7 samples at 18 ppm. One 18 ppm sequence covered the
RT fragment only and one sequence generated by NGS failed the inclusion criteria due to a
low number of reads. In total 52 samples were analysed by NGS. The mean read length ranged
from minimal 137 to maximal 219 bp. After pre-processing, ~18.000 to ~537.000 valid reads
led to mean coverages of ~1.100 to ~126.000.
Viral loads could be detected in 42/49 (85.7%) baseline samples (median 4.9x103; IQR
1.2x104-1.1x103), in 3/5 12 ppm samples and 7/7 18 ppm samples. For all three samples with
HIV-1 drug resistance development following option B+ for PMTCT
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Fig 1. Sample availability.
https://doi.org/10.1371/journal.pone.0178297.g001
Table 1. Outcome sample analysis.
N (%) No. PCR Viral load tested for Succesful NGS for
positive of No. of samples and No. of samples
No. analysed median viral load (IQR) analysed and
in copies/ml sequence results
No. of women included in 49
DRM analysis




No. of samples taken at time point
6 ppw 43 (87.8) 2/3 2/2 2/2
4.1x103 2 PR-RT
(5.1x103-3.2x103)
6 ppm 44 (89.8) 3/3 3/3 3/3
1.5x104 3 PR-RT
(1.8x104-9.3x103)
12 ppm 45 (91.8) 5/45 5/5 5/5
1.1x104 5 PR-RT
(1.3x104-0)
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VF, defined as viral loads >1000 copies/ml, at 12 ppm the respective 18 ppm sample likewise
displayed VF. In total, 3/45 and 7/43 women at 12 and 18 ppm (corresponding to 7/49 women
at 12/18 ppm) experienced VF corresponding to 93.3% and 85.7% of women at 12 and 18 ppm
reaching viral suppression.
Drug resistance mutations at baseline and subtyping
According to the sequence availability of baseline samples TDRMs in the PR and RT of HIV-1
could be analysed for 33 and 29 of 35 women, respectively (Table 1). In none of the 29 RT-
sequences NRTI- or NNRTI-selected mutations according to the WHO-SDRM list[33] could
be detected. Likewise, no PI-selected TDRMs were found in the 33 PR-sequences. However,
considering the IAS-USA mutation list[32] the Q58E mutation in the PR was detected in one
sample at baseline. Furthermore, a large number of minor PI resistance mutations were found
in the baseline samples[32]. The most prevalent minor PI resistance mutation was M36I (31/
33), followed by H69K (24/33) and L89M (20/33). Further detected minor PI resistance muta-
tions were L10I and L10V (each 1/33), G16E (4/33), K20I and K20R (4/33 and 10/33, respec-
tively), 33 (1/33), D60E (4/33), I62V (5/33), L63P (11/33), I64V and I64M (10/33and 1/33,
respectively), V82I (3/33) and I93L (1/33).
HIV-1 subtypes were determined from PR-RT baseline sequences of 35 women. Subtype
A1 was predominant in the study cohort (19/35; 54.3%), followed by subtype D (7/35; 20.0%).
14.3% (5/35) of women were infected with recombinant HIV-1 strains, while 8.6% (3/35) and
2.9% (1/35), were infected with subtype G and C HIV-1, respectively.
Drug resistance mutations at 12 and 18 ppm
HIV-1 RT genomic region could be analysed for 5/5 12 ppm and 6/7 18 ppm samples, corre-
sponding to seven women (Table 1). DRMs were detected in 3/5 12 ppm and 3/6 18 ppm
HIV-1 samples (Table 2), corresponding to three women. Hence, HIV-1 DRMs were detected
in 3/49 (6.1%) women at 12 and/or 18 ppm.
In one woman (Sample ID 1) HIV-1 resistance against EFV and NVP caused by the K103N
mutation in the RT was selected. This woman had reported full adherence until 12 ppm and
stated at 18 ppm not having taken pills for >seven days. The two other women (Sample ID 2
and 3) showed dual-class drug resistance against NRTIs and NNRTIs, including all drugs rec-
ommended for first-line ART. In both women, mutations K103N, P225H and M184V were
detected, although they reported full adherence until 18 ppm. Outcome of the DRM analysis
for the remaining 46 women is listed in S1 Table.
Low-frequency drug resistant viral variants were found in only one of the three women
at 18 ppm (Sample ID 3: V108I 6.0% and A98G 4.4%). At 12 ppm, low-frequency drug resis-
tant variants were detected in another woman (Sample ID 2: P225H 13.6%). Furthermore,
low-frequency drug resistant variants–but below the defined cut-off dependent on the viral
load of the sample—were also found in two women at 12 ppm (Sample ID 1: K103N 6.3% and
sample ID 3: L210W 4.3%). Nevertheless, all low-frequency drug resistant variants found at
12 ppm, independent if below or above the defined NGS cut-off, were detected in the respec-
tive 18 ppm sample selected as main viral variant (Table 2). All women with DRMs at 12/18 ppm
were of subtype D.
Discussion
Our study is among the first to provide data on the selection of DRMs until at least 1 year after
initiation of Option B+ for PMTCT.
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According to WHO recommendations the success of HIV-1 drug treatment is defined by a
viral load suppression in>85% of individuals after 12 months of ART [36]. This criterion was
met in our study with 93.3% (42/45) of women at 12 and 85.7% (36/43) at 18 ppm reaching
viral suppression. First results of women enrolled in Option B+ in Malawi (recommended first-
line regimen: EFV/3TC/TDF) report viral suppression in 91.5% of women at 12 ppm, which is
comparable to our results[24]. Data from other countries implementing Option B+ are not
available until now. However, in another study from Malawi, where pregnant women initiating
cART between 2008 and 2011 were followed up until 24 ppm, viral suppression was achieved in
87.1% of women at 12 and 89.9% at 18 ppm, respectively[37]. In a cohort of pregnant women in
Tanzania, women initiating cART between 2004 and 2006 had a viral suppression rate of only
47% at 12 ppm[38]. However, in both studies, women initiated cART for their own health due
to a low CD4 cell count at baseline. Furthermore, in both settings an NVP-based drug regimen
was the first-line recommendation at the time of study. Therefore, these data are not directly
comparable to the data from our study, where drug naïve women initiated cART independent
Table 2. Outcome of detection of DRMs in three women.
Sample Baseline 6 ppw 6 ppm 12 ppm 18 ppm
ID
1 VL 1.2x104 6.0x103 1.5x104 1.3x104 4.8x104
(copies/ml)
RT-PCR pos pos pos pos pos
DRMs (%) wt wt *K103N (16.8) **K103N (6.32) K103N (82.2)
2 VL 5.5x104 - 3.5x103 1.1x104 5.8x103
(copies/ml)
RT-PCR pos neg pos pos pos
DRMs (%) wt ns K70E (99.6) K70E (99.7) K70E (99.7)
M184V (99.4) M184V (99.5) M184V (96.8)
K103N (99.2) K103N (99.1) K103N (99.4)
E138Q (99.3) E138Q (99.5) V108I (29.6)
*P225H (13.6) E138Q (99.6)
P225H (76.2)
3 VL 2.0x104 2.2x103 2.1x104 1.7x104 1.3x105
(copies/ml)
RT-PCR neg pos pos pos pos
DRMs (%) ns M184V (85.4) M184V (94.7) M184V (97.2) M41L (41.7)
K103N (84.2) T215Y (21.5) **L210W (4.3) L74V (35.0)
V179T (32.2) K103N (89.4) T215Y (90.4) M184V (99.4)








VL: viral load; wt: wild type; nd: not detected; ns: no sequence from sample; -: exclusion according to sample inclusion criterion
* Low-frequency drug resistant variant
** Low-frequency drug resistant variant below the NGS cut-off, defined dependent on viral load.
https://doi.org/10.1371/journal.pone.0178297.t002
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of CD4 cell count. The high virological suppression rates in our study as in Malawi support the
latest WHO guidelines moving away from different “options” for PMTCT to the early, lifelong
cART initiation for all pregnant HIV-1 positive women regardless of clinical or CD4 cell count
or stage of disease[39]. Nevertheless, a known problem assessing the potential success of PMTCT
interventions in low-income settings is the high number of women lost to follow-up[40]. Taking
into account the loss to follow-up rate of 52.4% in this study, the true viral suppression rate is
probably much lower and fails to meet the criteria for successful HIV-1 drug treatment. Further-
more, using the reversed approach of testing in our study–conventional RT-PCR followed by
viral load measurement–we might have missed women with detectable viral load (due to the sen-
sitivity of the conventional RT-PCR of1000 copies/ml). However, the application of both
assays (RT-PCR and viral load measurement) to all baseline samples revealed only 7/49 RT-PCR
negative samples with viral load (which was below 1000 copies/ml for all seven cases) indicating
that all women experiencing VF were identified by our testing scheme.
It has been shown that stopping and restarting an NNRTI-based regimen poses a risk for
emergence of DRMs and may influence suppression rates when restarting a similar regimen
[13, 41]. In our study, DRMs were detected in 6.1% (3/49) of women at 12 and/or 18 ppm.
The absence of DRMs in the sequence of baseline samples of two women (Sample ID 1+2)
enabled to identify the DRMs at 12/18 ppm as newly acquired (Table 2). For the third woman
(Sample ID 3) the corresponding baseline viral sequence was missing due to a negative result
in the two conventional RT-PCR assays. However, increasing levels of DRMs from 6 ppw up
to highest levels at 18 ppm points to an ongoing selection of DRMs. Among women displaying
VF almost half of them (42.9%; 3/7) selected for HIV-1 DRMs. Two of them harboured multi-
ple DRMs, resulting in dual-class resistance against NRTIs and NNRTIs, including those rec-
ommended as first-line therapy for Option B+ (EFV/3TC/TDF). Although all three women
reported full or almost full adherence, the selection of drug resistance mutations as well as the
nearly constant detection of viral loads above 1000 copies/ml in the follow-up samples indicate
suboptimal drug concentrations. However, besides drug adherence, other factors like pharma-
cogenomic issues or drug interactions with additional therapeutic agents against co-morbidi-
ties might contribute to changes in drug levels or drug half life, resulting in the development
of DRMs[42]. Furthermore Kyeyune et al., observed a higher frequency of treatment failure
and drug resistance in subtype D versus subtype A infected individuals[43]. All three women
experiencing treatment failure in this study were of subtype D indicating a possible influence
of the subtype, maybe in combination with other adverse factors, on treatment success. How-
ever, to confirm this hypothesis a closer examination of more subtype D infected individuals
with and without treatment failure would be required. The NNRTI-associated mutation
K103N was observed in all these three women remarkably present as the main viral variant. In
Malawi, where low-frequency HIV-1 drug resistant variants were not analysed, DRMs were
present in 8.5% of women at 12 ppm, corresponding to a comparable percentage of 40% for
women with detectable viral load. In line with our results, they also detected the K103N in all
women with DRMs. In the above mentioned studies from Tanzania and Malawi with women
initiating life-long cART due to low CD4 counts, DRMs were observed in 34% and 6% of
women at 12 ppm, respectively[37, 38]. However, in the Malawian cohort only 15/27 samples
with detectable HIV-1 RNA were sequenced, which possibly leads to underestimation of the
DRM. Data from the pre-Option B+ era report DRMs (including low-frequency variants) in
40% of infected Tanzanian women receiving a drug regimen resembling Option A between
delivery and 16 weeks postpartum[6]. Compared to these findings, the rate of 6.1% of women
with DRMs at 12 and/or 18 ppm in this study and 8.5% at 12 ppm in Malawi clearly show the
benefit over earlier PMTCT recommendations. Nevertheless, the high number of women lost
to follow-up in this study (65/124; 52.4% of women) has to be considered. Women lost to
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follow-up probably also may have been less adherent to the regimen thereby impeding treat-
ment success. Therefore, the true percentage of DRMs is difficulty to assess and is probably
underestimated in this study analysing the more adherent women.
Low frequency variants of NNRTI-associated DRMs were detected in two of three women
at 12 and 18 ppm. However, their contribution to VF cannot be assessed, as they were found
among multiple DRMs. Several studies indicated that low-frequency drug resistant variants
are associated with VF[19]. In a recent systematic review of literature it has been shown that
individuals with low-frequency drug resistant variants and <95% medication adherence had a
5.1 times higher risk of VF compared to individuals with low-frequency drug resistant variants
and a medication adherence of>95%[44]. Kyeyune et al., reported the presence of DRMs in
low frequency only for 65% of Ugandan patients failing cART [45]. However, in other studies
no association between VF and the presence of low-frequency drug resistant variants was
observed[46, 47].
No TDRMs according to the WHO SDRM list were detected in women at baseline in our
study cohort. However, based on the algorithm of the IAS-USA, a number of minor PI-resis-
tance mutations were detected at baseline. These mutations are common non-B subtype poly-
morphisms, some of which have been associated with early treatment failure and higher
number of acquired major PI-associated mutations at time of treatment failure under a PI con-
taining regimen[48–50]. This should be kept in mind when switching to a PI containing sec-
ond-line regimen, as treatment success might me impaired. In total, the prevalence rate of
TDRMs in this study was 0%, although highly sensitive NGS was performed. Other studies
from Uganda report varying rates of TDRMs between 1.5% and 19% with respect to different
populations, regions and surveillance strategies[51, 52]. In pregnant ART-naïve women, two
studies between 2006 and 2007 observed TDRM rates ranging from 0% to 5%, respectively[53,
54]. These data are in line with the rate found in our study cohort.
The small sample size is a major limitation of our study as only 49 women with a respective
baseline sample could be followed-up until 12/18 ppm. However, limited samples sizes in the
context of HIV-1 positive cohort FU are a common problem in these settings, while at the
same time, our data are among the first to describe the development of DRMs in HIV-1 posi-
tive pregnant women starting Option B+ in a real-life scenario. For a growing number of
countries, now implementing the lifelong intake of cART for PMTCT, these data are encour-
aging with regards to DRMs linked with the initiation of an early lifelong treatment for all
HIV-positive pregnant women. For the future, data from large-scale, multicentre studies
assessing the emergence of DRMs during Option B+ will be required to confirm the findings
of this research.
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